Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.

Ruddy, Jake A; Boyarsky, Brian J; Bailey, Justin R; Karaba, Andrew H; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Durand, Christine M; Werbel, William A

Ruddy, Jake A; Boyarsky, Brian J; Bailey, Justin R; Karaba, Andrew H; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Durand, Christine M; Werbel, William A.

Ruddy JA; Department of Surgery.
Boyarsky BJ; Department of Surgery.
Bailey JR; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine.
Karaba AH; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine.
Garonzik-Wang JM; Department of Surgery.
Segev DL; Department of Surgery.
Durand CM; Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Werbel WA; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine.

AIDS ; 35(14): 2399-2401, 2021 11 15.

Article in English | MEDLINE | ID: covidwho-1309676

ABSTRACT

ABSTRACT

This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.

Subject(s)

COVID-19; HIV Infections; Antibodies, Viral; Antibody Formation; Humans; RNA, Messenger; SARS-CoV-2; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: AIDS Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google